Comparative study of sucralfate versus cimetidine in the treatment of acute gastroduodenal ulcer. Randomized trial with 667 patients.

Six-hundred sixty-seven patients with endoscopically proven peptic ulcer were included in a randomized, multicenter trial to assess the comparative efficacy of sucralfate and cimetidine. One hundred eighty-seven patients with gastric ulcer and 480 patients with duodenal ulcer completed the study. Ulcer healing was evaluated endoscopically at six weeks for duodenal ulcer and at eight weeks for gastric ulcer.

Intramyocardial distribution of hydroquinidine in the dog.

Hydroquinidine concentrations were measured simultaneously in the plasma and in right atrial and ventricular biopsy samples of four dogs in the steady state after eight days of oral sustained release hydroquinidine administration. The right ventricular concentrations were greater than the plasma concentrations in all samples (ratio 5.02(2.

[Sucralfate: development of a new concept of anti-ulcer treatment. Review of its pharmacodynamic properties].

Sucralfate, a new drug for peptic ulcer disease, is a sulfated disaccharide, basic aluminium sucrose sulfate complex. Its development is the result of a lot studies on sulfated polysaccharides, well-known for their antipeptic activities and also, for their anticoagulant activities. Sucralfate is free from toxicity, including anticoagulant activity like all the disaccharides and is an antiulcer agent better than other drugs of its chemical family.